• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

作者信息

Lyon Alexander R, López-Fernández Teresa, Couch Liam S, Asteggiano Riccardo, Aznar Marianne C, Bergler-Klein Jutta, Boriani Giuseppe, Cardinale Daniela, Cordoba Raul, Cosyns Bernard, Cutter David J, de Azambuja Evandro, de Boer Rudolf A, Dent Susan F, Farmakis Dimitrios, Gevaert Sofie A, Gorog Diana A, Herrmann Joerg, Lenihan Daniel, Moslehi Javid, Moura Brenda, Salinger Sonja S, Stephens Richard, Suter Thomas M, Szmit Sebastian, Tamargo Juan, Thavendiranathan Paaladinesh, Tocchetti Carlo G, van der Meer Peter, van der Pal Helena J H

机构信息

United Kingdom.

Spain.

出版信息

Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465. doi: 10.1093/ehjci/jeac106.

DOI:10.1093/ehjci/jeac106
PMID:36017575
Abstract
摘要

相似文献

1
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465. doi: 10.1093/ehjci/jeac106.
2
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
3
[2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)].[2022年欧洲心脏病学会与欧洲血液学协会（EHA）、欧洲治疗放射学和肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心血管肿瘤学指南]
G Ital Cardiol (Rome). 2023 Feb;24(2 Suppl 1):e1-e130. doi: 10.1714/3967.39463.
4
Erratum to: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC).勘误：《2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南》：由欧洲心脏病学会（ESC）心脏肿瘤学特别工作组制定。
Eur Heart J. 2023 May 7;44(18):1621. doi: 10.1093/eurheartj/ehad196.
5
Erratum: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC).勘误：2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心血管肿瘤学指南：由欧洲心脏病学会（ESC）心血管肿瘤学特别工作组制定。
Eur Heart J Cardiovasc Imaging. 2023 May 31;24(6):e98. doi: 10.1093/ehjci/jead080.
6
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).心血管影像学在接受心脏毒性治疗的癌症患者中的作用：代表心力衰竭协会（HFA）、欧洲心血管影像协会（EACVI）和欧洲心脏病学会心脏肿瘤学委员会（ESC）的立场声明。
Eur J Heart Fail. 2020 Sep;22(9):1504-1524. doi: 10.1002/ejhf.1957. Epub 2020 Aug 21.
7
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.血清生物标志物在接受心脏毒性癌症治疗的癌症患者中的作用：心力衰竭协会的心脏肿瘤学研究小组和欧洲心脏病学会的心脏肿瘤学理事会的立场声明。
Eur J Heart Fail. 2020 Nov;22(11):1966-1983. doi: 10.1002/ejhf.2017. Epub 2020 Oct 20.
8
[The Cardio-Oncology Guideline - A Comprehensive Approach to Managing Cardiovascular Risks in Cancer Patients].[心脏肿瘤学指南——癌症患者心血管风险管理的综合方法]
Dtsch Med Wochenschr. 2024 Jun;149(12):719-723. doi: 10.1055/a-2104-6363. Epub 2024 May 23.
9
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.计划接受心脏毒性癌症治疗的癌症患者的基线心血管风险评估：心力衰竭协会欧洲心脏病学会的心脏肿瘤学研究小组与国际心脏肿瘤学会合作的立场声明和新的风险评估工具。
Eur J Heart Fail. 2020 Nov;22(11):1945-1960. doi: 10.1002/ejhf.1920. Epub 2020 Aug 6.
10
Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM).核医学在评估和预防癌症治疗相关的心脏毒性方面的应用：欧洲核医学协会（EANM）的应用前景和建议。
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):792-812. doi: 10.1007/s00259-022-05991-7. Epub 2022 Nov 5.

引用本文的文献

1
Asymptomatic Troponin Elevation and Early Mortality Following Immune Checkpoint Inhibitor Therapy in Patients Without Cardiac Adverse Events.在无心脏不良事件的患者中，免疫检查点抑制剂治疗后无症状肌钙蛋白升高与早期死亡率
Cancer Diagn Progn. 2025 Sep 1;5(5):634-641. doi: 10.21873/cdp.10479. eCollection 2025 Sep-Oct.
2
Coronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC Study.冠状动脉钙化评分作为蒽环类药物所致心脏毒性的预测指标：ANTEC研究
Pharmaceuticals (Basel). 2025 Jul 25;18(8):1102. doi: 10.3390/ph18081102.
3
Smoking behavior changes and risk of cardiovascular diseases after cancer diagnosis: a nationwide cohort study.
癌症诊断后吸烟行为的变化及心血管疾病风险：一项全国性队列研究。
Support Care Cancer. 2025 Aug 27;33(9):813. doi: 10.1007/s00520-025-09869-w.
4
Artificial intelligence-enhanced echocardiography in cardiovascular disease management.人工智能增强型超声心动图在心血管疾病管理中的应用
Nat Rev Cardiol. 2025 Aug 5. doi: 10.1038/s41569-025-01197-0.
5
Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials.乳腺癌中蒽环类药物所致心脏毒性的药物干预：一项随机对照试验的系统评价和荟萃分析
Breast Cancer Res Treat. 2025 Nov;214(1):1-23. doi: 10.1007/s10549-025-07791-7. Epub 2025 Aug 5.
6
Left Ventricular Function and Echocardiographic Parameters in Patients Undergoing Chemotherapy With 5-Fluorouracil, Anthracycline, Taxotere, and Herceptin: Prospective Cohort Study.接受5-氟尿嘧啶、蒽环类抗生素、多西他赛和赫赛汀化疗患者的左心室功能及超声心动图参数：前瞻性队列研究
Health Sci Rep. 2025 Jul 27;8(8):e71031. doi: 10.1002/hsr2.71031. eCollection 2025 Aug.
7
Explainable machine learning for neoplasms diagnosis via electrocardiograms: an externally validated study.通过心电图进行肿瘤诊断的可解释机器学习：一项外部验证研究。
Cardiooncology. 2025 Jul 26;11(1):70. doi: 10.1186/s40959-025-00370-1.
8
Diagnosis, clinical management, and emerging strategies for coronary artery disease in patients with cancer.癌症患者冠状动脉疾病的诊断、临床管理及新出现的策略
Am Heart J Plus. 2025 Jun 26;56:100568. doi: 10.1016/j.ahjo.2025.100568. eCollection 2025 Aug.
9
Fertility preservation in females requiring gonadotoxic therapy should be more than freezing measures before therapy - secondary fertility preservation and menopause care management after therapy should also be considered.对于需要接受性腺毒性治疗的女性，生育力保存不应仅限于治疗前的冷冻措施，还应考虑治疗后的二次生育力保存及绝经护理管理。
Arch Gynecol Obstet. 2025 Jul 12. doi: 10.1007/s00404-025-08104-5.
10
Statins: Novel Approaches for the Management of Doxorubicin-Induced Cardiotoxicity-A Literature Review.他汀类药物：多柔比星诱导的心脏毒性管理的新方法——文献综述
Cardiovasc Toxicol. 2025 Jul 10. doi: 10.1007/s12012-025-10030-6.